Get the Stockscreener App
0.90
3.24%
-0.0301
After Hours:
.87
-0.03
-3.33%
Barinthus Biotherapeutics Plc Adr stock is traded at $0.90, with a volume of 13,154.
It is down -3.24% in the last 24 hours and down -16.67% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
See More
Previous Close:
$0.9301
Open:
$0.91
24h Volume:
13,154
Relative Volume:
0.40
Market Cap:
$38.73M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-0.4688
EPS:
-1.92
Net Cash Flow:
$-56.34M
1W Performance:
+1.88%
1M Performance:
-16.67%
6M Performance:
-25.50%
1Y Performance:
-37.06%
1-Day Range:
$0.90
$0.935
1-Week Range:
$0.891
$0.9499
52-Week Range:
$0.64
$1.58
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.90 | 38.73M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
BRNS stock touches 52-week low at $0.8 amid market volatility - Investing.com UK
Dollar General Corp (DG) Shares Up Despite Recent Market Volatility - The News Heater
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - MSN
Exclusive-Mexico's Pemex, billionaire Slim renegotiate deepwater gas project - Yahoo Finance
RBC raises Reckitt Benckiser stock target to £57.00, keeps outperform - MSN
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
The big rebrand: Why these 4 biopharmas changed their name this year - PharmaVoice
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Mexico Shingles Vaccine Market Size & Outlook, 2023-2030 - Grand View Research
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):